1064 related articles for article (PubMed ID: 1694234)
1. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
2. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
3. Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Northup JK; Gadre SA; Ge Y; Lockhart LH; Velagaleti GV
Eur J Haematol; 2007 Feb; 78(2):152-6. PubMed ID: 17313561
[TBL] [Abstract][Full Text] [Related]
4. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
Vose JM; Anderson JR; Bierman PJ; Bast M; Weisenburger D; Chan WC; Bishop MR; Armitage JO
Semin Hematol; 1994 Apr; 31(2 Suppl 3):4-8. PubMed ID: 7521065
[No Abstract] [Full Text] [Related]
5. Bone marrow involvement by non-Hodgkin's lymphom.
Lee WI; Lee JH; Kim IS; Lee KN; Kim SH
J Korean Med Sci; 1994 Oct; 9(5):402-8. PubMed ID: 7702789
[TBL] [Abstract][Full Text] [Related]
6. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation.
Pittaluga S; Bijnens L; Teodorovic I; Hagenbeek A; Meerwaldt JH; Somers R; Thomas J; Noordijk EM; De Wolf-Peeters C
Blood; 1996 May; 87(10):4358-67. PubMed ID: 8639796
[TBL] [Abstract][Full Text] [Related]
7. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation.
Morra E; Lazzarino M; Castello A; Inverardi D; Coci A; Pagnucco G; Orlandi E; Merante S; Magrini U; Zei G
Eur J Haematol; 1989 May; 42(5):445-53. PubMed ID: 2471652
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
Armitage JO; Vose JM; Linder J; Weisenburger D; Harrington D; Casey J; Bierman P; Sorensen S; Hutchins M; Moravec DF
J Clin Oncol; 1989 Dec; 7(12):1783-90. PubMed ID: 2585020
[TBL] [Abstract][Full Text] [Related]
11. Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Barista I; Tekuzman G; Firat D; Baltali E; Kansu E; Kars A; Ozisik Y; Ruacan S; Uzunalimoğlu B; Karaağaoğlu E
Jpn J Cancer Res; 1994 Dec; 85(12):1200-7. PubMed ID: 7531679
[TBL] [Abstract][Full Text] [Related]
12. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
13. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
[TBL] [Abstract][Full Text] [Related]
14. Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
Heinz R; Hanak H; Stacher A
Klin Wochenschr; 1985 Jul; 63(14):619-26. PubMed ID: 3839867
[TBL] [Abstract][Full Text] [Related]
15. Primary peripheral nodal lymphoma in children.
Wollner N; Exelby P; Lindsley KL; Lieberman P; Filippa D; Heller G
Cancer; 1993 Jun; 71(11):3670-9. PubMed ID: 8490916
[TBL] [Abstract][Full Text] [Related]
16. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy for non-Hodgkin's lymphoma].
Kuraishi Y; Usui N; Dobashi N
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2210-6. PubMed ID: 9881077
[TBL] [Abstract][Full Text] [Related]
18. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
Chubachi A; Miura AB; Yamaguchi A; Nishimura S
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
[TBL] [Abstract][Full Text] [Related]
19. Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement.
Oh KC; Zang DY
Korean J Intern Med; 2003 Mar; 18(1):40-4. PubMed ID: 12760267
[TBL] [Abstract][Full Text] [Related]
20. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.
Vose JM; Armitage JO; Weisenburger DD; Bierman PJ; Sorensen S; Hutchins M; Moravec DF; Howe D; Dowling MD; Mailliard J
J Clin Oncol; 1988 Dec; 6(12):1838-44. PubMed ID: 2462026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
